Journal
PROTEOMICS CLINICAL APPLICATIONS
Volume 2, Issue 10-11, Pages 1386-1402Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.200780174
Keywords
Biomarker verification; Multiple reaction monitoring; Targeted proteomics
Funding
- National Cancer Institute's Clinical Proteomic Technologies for Cancer
- Entertainment Industry Foundation
- Paul G. Allen Family Foundation
- NATIONAL CANCER INSTITUTE [U24CA126476] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The application of omics technologies to biological samples generates hundreds to thousands of biomarker candidates; however, a discouragingly small number make it through the pipeline to clinical use. This is in large part due to the incredible mismatch between the large numbers of biomarker candidates and the paucity of reliable assays and methods for validation studies. We desperately need a pipeline that relieves this bottleneck between biomarker discovery and validation. This paper reviews the requirements for technologies to adequately credential biomarker candidates for costly clinical validation and proposes methods and systems to verify biomarker candidates. Models involving pooling of clinical samples, where appropriate, are discussed. We conclude that current proteomic technologies are on the cusp of significantly affecting translation of molecular diagnostics into the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available